Drugs that potentiate the effects of epinephrine include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin ... Fresenius Kabi ...

The FDA designated Fresenius Kabi's Otulfi® (ustekinumab-aauz) as an interchangeable biosimilar to the reference product Stelara® (ustekinumab). The FDA designated Fresenius Kabi's Otulfi ...

Planegg-Martinsried, Germany – Formycon AG (FSE: FYB, Prime Standard, “Formycon”) and its commercialization partner Fresenius Kabi announce today that the U.S. Food and Drug Administration (FDA) ...

LAKE ZURICH, Ill. - Fresenius Kabi, a health care company and part of the Fresenius Group, with a market capitalization of $447 million and a "FAIR" overall financial health rating according to ...

Fresenius Kabi is a global leader in supplying blood collection bags and devices, supporting blood banks and health care facilities worldwide. The company’s I.V. Generics and Fluids for infusion ...

(RTTNews) - Formycon AG (0W4N.L) along with its commercialization partner Fresenius Kabi, Monday announced that the U.S. Food and Drug Administration designated FYB202/Otulfi as interchangeable ...

May 05, 2025--(BUSINESS WIRE)--BioLife Plasma Services, part of Takeda (TSE:4502/NYSE:TAK), today announced that it has begun introducing the new Fresenius Kabi Adaptive Nomogram across its U.S ...

LAKE ZURICH, Ill. - Fresenius Kabi, a health care company and part of the Fresenius Group, with a market capitalization of $447 million and a "FAIR" overall financial health rating according to ...

The European Commission has approved the first biosimilar version of Actemra/RoActemra, Roche’s $3 billion blockbuster, from German drugmaker Fresenius Kabi. The biosimilar of IL-6 inhibitor ...

BioLife Plasma Services, part of Takeda (TSE:4502/NYSE:TAK), today announced that it has begun introducing the new Fresenius Kabi Adaptive Nomogram across its U.S. network of plasma donation centers.

The joint company will be 55% owned by Vifor Pharma and 45% by Fresenius Kabi. Fresenius Kabi will be fully responsible for the marketing of Vifor’s intravenous iron portfolio in China.